文献速递腹部CT

CT诊断的胰腺外侵犯是胰腺导管腺癌更可靠的生存预后因素

CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extension.
PubMed 文献 · Eur Radiol · 2021-07-14

回顾性纳入87例切除的胰腺导管腺癌患者,由两名放射科医师评估CT诊断的胰腺外侵犯(阳性定义为肿瘤周围条索影和/或膨胀性生长)。CT诊断的胰腺外侵犯在单变量和多变量分析中均为无病生存和总生存的独立预后因素,风险比高于病理诊断的胰腺外侵犯。

要点

  • CT诊断胰腺外侵犯(条索影或膨胀性生长)与更差的无病生存和总生存独立相关。
  • 肿瘤接触胰腺表面但无条索影/膨胀性生长者,生存与肿瘤被胰腺实质包围者相似。
  • CT诊断胰腺外侵犯预测病理侵犯的准确性低,但重复性高(κ=0.82)。

关键影像表现/征象

  • CT诊断的胰腺外侵犯阳性表现为肿瘤周围条索影和/或膨胀性生长。
  • CT诊断胰腺外侵犯阴性包括肿瘤被胰腺实质包围(类别i)和肿瘤接触胰腺表面(类别ii)。
  • CT诊断胰腺外侵犯阳性42/87例(48.3%),观察者间一致性κ=0.82。

诊断标准与关键数值

  • CT诊断胰腺外侵犯阳性标准:肿瘤周围条索影和/或膨胀性生长。
  • CT诊断胰腺外侵犯阴性标准:肿瘤被胰腺实质包围(类别i)或肿瘤接触胰腺表面(类别ii)。
  • CT诊断胰腺外侵犯对无病生存的单变量HR为5.30(p<0.01),多变量HR为4.22(p<0.01)。
  • CT诊断胰腺外侵犯对总生存的单变量HR为5.31(p<0.01),多变量HR为4.38(p<0.01)。
  • 45例无CT诊断胰腺外侵犯的肿瘤中,病理诊断胰腺外侵犯在CT类别i中为2/8(25.0%),在CT类别ii中为32/37(86.5%)。

临床应用与阅片要点

  • 阅片时应关注肿瘤周围条索影和膨胀性生长,阳性者提示预后较差。
  • 肿瘤仅接触胰腺表面但无条索影/膨胀性生长时,生存与肿瘤被胰腺实质包围者相似,尽管病理侵犯率较高。

局限性

  • 回顾性研究设计。
  • 样本量有限(87例)。
  • CT预测病理胰腺外侵犯的诊断准确性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine the correlation between CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma (PDAC), pathology-diagnosed extra-pancreatic extension, and survival in patients with PDAC.

METHODS: This retrospective study included 87 patients with resected PDAC. Two radiologists evaluated negative ((i) tumours surrounded by the pancreatic parenchyma and (ii) tumours contacting the pancreatic surface) or positive ((iii) tumours with peri-pancreatic strand appearances and/or with expansive growth) CT-diagnosed extra-pancreatic extension. Clinical, pathological, and CT imaging characteristics predicting disease-free survival (DFS) and overall survival (OS) were assessed using Cox proportional-hazards models. Diagnostic accuracy for pathology-diagnosed extra-pancreatic extension was also assessed.

RESULTS: CT-diagnosed extra-pancreatic extension (42/87 tumours, 48.3%; κ = 0.82) had a higher hazard ratio (HR) for the DFS (HR, 5.30; p < 0.01) and OS (HR, 5.31; p < 0.01) rates than pathology-diagnosed extension in univariable analyses. It was also an independent prognostic factor for the DFS (HR, 4.22; p < 0.01) and OS (HR, 4.38; p < 0.01) rates in multivariable analyses. Of 45 tumours without CT-diagnosed extra-pancreatic extension, pathology-diagnosed extra-pancreatic extension was observed in 2/8 (25.0%) and 32/37 (86.5%) tumours with CT categories (i) and (ii), respectively. However, the differences in the survival rates between patients with CT categories (i) and (ii) were insignificant, although those in the latter category had significantly better survival rates than those with CT-diagnosed extra-pancreatic extension (category (iii)).

CONCLUSIONS: CT-diagnosed extra-pancreatic extension was a better prognostic factor than pathology-diagnosed extension and considered an independent factor for the postoperative DFS and OS rates with reasonable frequency and high reproducibility, despite the low diagnostic accuracy for predicting pathology-diagnosed extra-pancreatic extension.

KEY POINTS: • A CT-diagnosed extra-pancreatic extension had a higher hazard ratio for both disease-free survival and overall survival compared to pathology-diagnosed extension in univariable survival analyses. • A CT-diagnosed extra-pancreatic extension was a significant independent predictor of both disease-free survival and overall survival, as observed in multivariable survival analyses. • Patients with tumours contacting with the pancreatic surface on CT images (CT category (ii)) showed similar survival rates to those whose tumours were surrounded by the pancreatic parenchyma (CT category (i)), although many tumours with CT category (ii) extended pathologically beyond the pancreas.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Toshima F, Inoue D, Yoshida K, et al. CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extension. Eur Radiol. 2021. PMID: 34263360. doi:10.1007/s00330-021-08180-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。